All In Biotech

Drug Trial Radar · NCT01350973

Efficacy of TAK-085 in Participants With Hypertriglyceridemia

A Phase 3, Multicenter, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of TAK-085 in Subjects With Hypertriglyceridemia.

Last checked: Nov 20, 2026Latest source record: Sep 20, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 611 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

611

Actual

Start

Nov 2009

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
May 10, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the efficacy and safety of TAK-085, once daily (QD) or twice daily (BID), compared to ethyl eicosapentaenoate (EPA-E), three times daily (TID) in participants with hypertriglyceridemia undergoing lifestyle modification.

Conditions

  • Hypertriglyceridemia

Interventions

  • Omega-3-acid ethyl esters 90 (TAK-085)Drug

    Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.

  • Eicosapentaenoic acid-ethyl (EPA-E)Drug

    EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change From Baseline in Triglyceride Level at the Final VisitTime frame: Baseline and 12 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.